Intercept Pharmaceuticals, Inc. (ICPT): Price and Financial Metrics


Intercept Pharmaceuticals, Inc. (ICPT): $19.02

-0.13 (-0.68%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ICPT to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ICPT POWR Grades

  • Value is the dimension where ICPT ranks best; there it ranks ahead of 95.8% of US stocks.
  • ICPT's strongest trending metric is Growth; it's been moving up over the last 177 days.
  • ICPT ranks lowest in Stability; there it ranks in the 18th percentile.

ICPT Stock Summary

  • Equity multiplier, or assets relative to shareholders' equity, comes in at -2.55 for INTERCEPT PHARMACEUTICALS INC; that's greater than it is for only 4.42% of US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, INTERCEPT PHARMACEUTICALS INC is reporting a growth rate of -529.51%; that's higher than just 3.28% of US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for ICPT comes in at 33.03% -- higher than that of 95.6% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to INTERCEPT PHARMACEUTICALS INC are SRDX, FKWL, KLIC, ESPR, and ONTX.
  • ICPT's SEC filings can be seen here. And to visit INTERCEPT PHARMACEUTICALS INC's official web site, go to www.interceptpharma.com.

ICPT Valuation Summary

  • In comparison to the median Healthcare stock, ICPT's price/earnings ratio is 83.71% lower, now standing at 3.6.
  • ICPT's price/sales ratio has moved down 97.8 over the prior 125 months.

Below are key valuation metrics over time for ICPT.

Stock Date P/S P/B P/E EV/EBIT
ICPT 2023-01-30 2.2 6.9 3.6 4.0
ICPT 2023-01-27 2.3 7.1 3.7 4.1
ICPT 2023-01-26 2.3 7.1 3.7 4.0
ICPT 2023-01-25 2.3 7.1 3.7 4.1
ICPT 2023-01-24 2.0 6.2 3.3 3.7
ICPT 2023-01-23 2.0 6.1 3.2 3.6

ICPT Growth Metrics

    The year over year net cashflow from operations growth rate now stands at 94.35%.
  • Its year over year cash and equivalents growth rate is now at -40.75%.
  • Its 5 year net income to common stockholders growth rate is now at 7.63%.
Over the past 33 months, ICPT's revenue has gone up $78,329,000.

The table below shows ICPT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 330.331 -18.121 206.361
2022-06-30 345.57 3.106 -64.724
2022-03-31 370.389 -7.113 -68.29
2021-12-31 363.468 -41.639 -91.426
2021-09-30 354.332 -61.467 -107.293
2021-06-30 341.026 -106.584 -170.13

ICPT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ICPT has a Quality Grade of B, ranking ahead of 77.14% of graded US stocks.
  • ICPT's asset turnover comes in at 0.66 -- ranking 47th of 682 Pharmaceutical Products stocks.
  • GBT, AVDL, and SYRS are the stocks whose asset turnover ratios are most correlated with ICPT.

The table below shows ICPT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.660 0.992 -0.066
2021-06-30 0.616 0.988 -0.139
2021-03-31 0.552 0.984 -0.191
2020-12-31 0.506 0.983 -0.239
2020-09-30 0.455 0.977 -0.277
2020-06-30 0.397 0.980 -0.282

ICPT Price Target

For more insight on analysts targets of ICPT, see our ICPT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $31.63 Average Broker Recommendation 1.92 (Hold)

ICPT Stock Price Chart Interactive Chart >

Price chart for ICPT

ICPT Price/Volume Stats

Current price $19.02 52-week high $21.25
Prev. close $19.15 52-week low $10.81
Day low $18.73 Volume 449,000
Day high $19.30 Avg. volume 733,257
50-day MA $14.99 Dividend yield N/A
200-day MA $15.42 Market Cap 787.75M

Intercept Pharmaceuticals, Inc. (ICPT) Company Bio


Intercept Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic underserved liver diseases. The company was founded in 2002 and is based in New York, New York.


ICPT Latest News Stream


Event/Time News Detail
Loading, please wait...

ICPT Latest Social Stream


Loading social stream, please wait...

View Full ICPT Social Stream

Latest ICPT News From Around the Web

Below are the latest news stories about INTERCEPT PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ICPT as an investment opportunity.

Intercept Surges To Four-Month High After Staving Off Amneal's Generic For 11 Years

Intercept reached a settlement with Amneal that delays a generic version of its only product. In response, ICPT stock surged Wednesday.

Yahoo | January 25, 2023

Does Intercept (ICPT) Have the Potential to Rally 52.08% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 52.1% in Intercept (ICPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Yahoo | January 20, 2023

Intercept's (ICPT) NDA for NASH Treatment Accepted By FDA

Intercept's (ICPT) new drug application (NDA) for obeticholic acid (OCA) for the treatment of nonalcoholic steatohepatitis gets accepted by the regulatory body in the United States.

Yahoo | January 20, 2023

FDA Accepts Intercept’s New Drug Application for OCA for the Treatment of Pre-Cirrhotic Liver Fibrosis Due to NASH

NDA is supported by robust NASH clinical development program, including two positive interim analyses from the Phase 3 REGENERATE study demonstrating OCA’s improvement in liver fibrosis without worsening of NASHPDUFA target action date set for June 22, 2023 MORRISTOWN, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseas

Yahoo | January 19, 2023

Intercept (ICPT) Gains 12.4% in the Past Six Months: Here's Why

Intercept (ICPT) gains 12% in the last six months on Ocaliva's positive performance and encouraging pipeline progress.

Yahoo | January 13, 2023

Read More 'ICPT' Stories Here

ICPT Price Returns

1-mo 31.35%
3-mo 24.15%
6-mo 14.17%
1-year 24.23%
3-year -80.63%
5-year -68.73%
YTD 53.76%
2022 -24.06%
2021 -34.05%
2020 -80.07%
2019 22.95%
2018 72.53%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7139 seconds.